Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 17/20 | 0.66 |
| ▸ | ATR | Q13535 | 13/20 | 0.66 |
| ▸ | ATRIP | Q8WXE1 | 13/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.66 |
| ▸ | ATM | Q13315 | 10/20 | 0.66 |
| ▸ | MTOR | P42345 | 4/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688073 | 0.81 | PRKDC (0.47) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23119277 | 0.80 | PRKDC (0.64) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL20374457 | 0.79 | PRKDC (0.67) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23119274 | 0.78 | ATM (0.44) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL30359513 | 0.77 | PRKDC (0.46) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL21541813 | 0.77 | PRKDC (0.46) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23093848 | 0.75 | ATM (0.61) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23093866 | 0.73 | ATM (0.76) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23093843 | 0.73 | PRKDC (0.58) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL23119176 | 0.73 | NPM1 (0.47) | PRKDCATRATRIPPIK3CBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119215050-A | Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs | 上海瑛派药业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119080781-A | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-114787162-B | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-11-10 | — | — | US | disclosed |
| CN-114787162-A | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4028400-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021047646-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | IMPACT THERAPEUTICS, INC (CN) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | CHEK2, CHEK1, ATM | PRKDC 26/4885ATR 8/4885ATRIP 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.